About AltheaDx
AltheaDx is a Healthcare company based in San Diego (United States) founded in 2009, and was acquired by Castle Biosciences in April 2022. Molecular diagnostics and biomarker discovery services are offered. AltheaDx has raised $94.73 million across 14 funding rounds from investors including Castle Biosciences, WuXi AppTec and 6 Dimensions Capital. AltheaDx offers products and services including IDgenetix, DecisionDx-Melanoma, DecisionDx-SCC, TissueCypher, and DecisionDx-UM. Its focus areas include Life Sciences, Clinical Genomics, Sequencing Based and Precision Medicine. Its legal entity is ALTHEADX, INC. Its competitors include Denali Therapeutics, Poseida Therapeutics and Castle Biosciences; 3 of its 3 listed competitors have raised funding.
Company details
AltheaDx, Inc. provides molecular diagnostics and PCR-based services. It offers molecular biomarker discovery, assay development, assay validation, and prospectiveretrospective clinical trial testing services. The company also provides gene expression and genotyping analysis for pre-clinical and clinical applications. In addition, it offers discovery services, such as microarray analysis, real-time PCR, next-gen sequencing, quantitative PCR, mutation scanning, data analysis, race assay, and therapeutic siRNA; and diagnostic development services. Further, the company provides clinical trial services, such as enhanced clinical trial, predictive drug response, patient stratification and monitoring.
- Headquarters San Diego, United States
- Stage Acquired
- SectorsHealthcare
- Website altheadx.com
- Social LinkedIn X YouTube
- Acquired by Castle Biosciences (Apr 2022)
- Legal Name Altheadx, Inc.
- Total Equity Funding$94.73M (USD)
in 14 rounds
- Latest Funding Round$3.73M (USD), Series D
Dec 2020
- InvestorsCastle Biosciences
& 5 more
- Acquired byCastle Biosciences
(Apr 2022)
Products & Services of AltheaDx
AltheaDx offers a comprehensive portfolio of products and services, including IDgenetix, DecisionDx-Melanoma, DecisionDx-SCC, TissueCypher, and DecisionDx-UM.
Analyzes genes to personalize mental health medications and predict responses.
Evaluates melanoma risk and guides treatment decisions based on genetic profiling.
Assists in assessing squamous cell carcinoma prognosis and management options.
Predicts cancer risk in gastroenterology through gene expression analysis.
Supports uveal melanoma diagnosis and metastatic risk evaluation.
Apps and channels of AltheaDx
its YouTube channel Castle Biosciences has 578 subscribers.
Funding Insights of AltheaDx
AltheaDx has successfully raised a total of $94.73M across 14 strategic funding rounds. The most recent funding activity was a Series D round of $3.73 million completed in December 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $94.73M
- Total Rounds 14
- Last Round Series D — $3.73M
- First Round $3.57M
(Aug 2009)
- Investors Count 5
Latest 10 of 14 funding rounds of AltheaDx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2020 | $3.73M | Series D | – | – | – |
| Oct 2019 | $1.32M | Series D | – | – | – |
| Jan 2019 | $1.68M | Series D | – | – | – |
| Jul 2018 | $1.97M | Series D | – | – | – |
| Feb 2018 | $830,610 | Series D | – | – | – |
| Apr 2017 | $27M | Series D | – | – | – |
| Feb 2017 | $3M | Series C | – | – | – |
| Sep 2016 | $6M | Series C | – | – | – |
| Jul 2016 | $2.22M | Series C | – | – | – |
| Dec 2015 | $30M | Series C | – | – |
6 investors in total: 6 institutional.
Investors in AltheaDx
AltheaDx has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Castle Biosciences, WuXi AppTec and 6 Dimensions Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Life-Sciences focused early and growth stage VC firm funding companies in China & the US | 6dimensionscapital.com | Pudong, China | ||
Private equity and hedge fund investments in healthcare are managed. | ally-bridge.com | Hong Kong, China | ||
Investment in conscious healthcare businesses is facilitated by ALMA. | almalifesciences.com | |||
Venture capital firm focused on life science, medical device and healthcare companies | thpartners.net | San Francisco, United States | ||
Provider of CRO and CDMO services | 2000 | wuxiapptec.com | Shanghai, China | |
Diagnostic tests for cancer prognosis are provided. | 2008 | castlebiosciences.com | Friendswood, United States |
Investor details for AltheaDx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of AltheaDx
40 people are tracked at AltheaDx (24 in leadership, 7 in board & advisors, 9 in team).
| Name | Role | Group |
|---|---|---|
Toby Juvenal | Chief Commercial Officer | Leadership |
Kristen Oelschlager | COO | Leadership |
Noreen Manning | VP, Reimbursement | Leadership |
John Abbott | VP, Finance | Leadership |
Kevin Doman | VP, Sales | Leadership |
Keli Greenberg | VP, Human Resources | Leadership |
Trisha Poteet | VP, Clinical Services | Leadership |
Sherri Borman | Executive Laboratory Director | Leadership |
Jay Braxton | VP, Medical Affairs | Leadership |
Chris Otte | VP, Information Technology | Leadership |
Camilla Zuckero | VP, Investor Relations & Corporate Affairs | Leadership |
Lj Delponte | Sales Director GI East | Leadership |
Ian Fladoos | Vice President Of Sales | Leadership |
Sameer Abdullah | Associate Director, Financial Planning & Analysis | Leadership |
Joshua Albers | Director, Software And Application Development | Leadership |
Matthew Goldberg | Senior Vice President, Medical | Leadership |
Derek Maetzold | Founder, President & CEO | Leadership |
Michael Maltby | Executive Director, Managed Care | Leadership |
Frank Stokes | CFO | Leadership |
Jason March | Product Director | Leadership |
20 more people are available in the full profile.
Complete people profiles for AltheaDx
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of AltheaDx
4 dated milestones of AltheaDx across 13 years, from founding to its latest funding, stage changes and deals.
- Founded AltheaDx is founded.
- Funding First funding round of $3.6M.
- Funding Latest funding round, Series D, of $3.7M.
- Exit Acquired by Castle Biosciences.
Competitors of AltheaDx
AltheaDx has 3 listed competitors in our database, 3 of them funded. They include Denali Therapeutics, Poseida Therapeutics and Castle Biosciences.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. | |
| poseida.com | 2015 | San Diego, United States | $323.78M | 259 | Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies | |
| cernostics.com | 2008 | Pittsburgh, United States | $14.18M | 16 | Precision diagnostic and prognostic tests are developed by Castle Biosciences. |
Detailed competitors of AltheaDx
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of AltheaDx
Websites that share an audience with AltheaDx (altheadx.com).
Websites whose visitors overlap most with AltheaDx. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| rarecyte.com | 100% | 3.2K | #5,681,690 | View details | |
| astx.com | 91% | 8.9K | #2,592,392 | View details | |
| molprofiles.co.uk | 90% | View details | |||
| intelgenx.com | 90% | View details | |||
| idifarma.com | 90% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 8 similar websites and full traffic analytics for AltheaDx
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 8 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as AltheaDx (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Altheadx
Complete news archive for AltheaDx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AltheaDx
AltheaDx was founded in 2009.
AltheaDx is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
AltheaDx is a funded company, having raised a total of $94.73M across 14 funding rounds to date. The company's 1st funding round was a Series C of $30M, raised on Aug 2009.
AltheaDx, Inc. provides molecular diagnostics and PCR-based services. It offers molecular biomarker discovery, assay development, assay validation, and prospectiveretrospective clinical trial testing services. The company also provides gene expression and genotyping analysis for pre-clinical and clinical applications. In addition, it offers discovery services, such as microarray analysis, real-time PCR, next-gen sequencing, quantitative PCR, mutation scanning, data analysis, race assay, and therapeutic siRNA; and diagnostic development services. Further, the company provides clinical trial services, such as enhanced clinical trial, predictive drug response, patient stratification and monitoring.
AltheaDx's top competitors include Poseida Therapeutics, Denali Therapeutics and Castle Biosciences.
AltheaDx offers IDgenetix, DecisionDx-Melanoma, DecisionDx-SCC, TissueCypher, and DecisionDx-UM.
AltheaDx has 6 investors. Key investors include Castle Biosciences, WuXi AppTec, 6 Dimensions Capital, Ally Bridge Group, and ALMA Life Sciences.
AltheaDx operates through Altheadx, Inc..
Yes. AltheaDx was acquired by Castle Biosciences in April 2022.